Leukemia

Study expands on effectiveness of AP23464, in Gleevec-resistant leukemia cells

Published in Biotech Business Week, April 26th, 2004

ARIAD Pharmaceuticals, Inc., (ARIA) announced that AP23464, its lead product candidate to treat certain forms of leukemia, is highly effective in blocking the growth of leukemia cells that harbor any of 30 different mutations in the Abl protein that confer resistance to Gleevec (imatinib) - today's mainstay of treatment for chronic myelogenous leukemia (CML).

The research - conducted by a team of scientists led by George Q. Daley, MD, PhD, of Harvard Medical School and presented at the American Association for Cancer Research annual meeting - shows that AP23464 effectively suppresses even those leukemia cells containing robust and common Gleevec-resistant mutants and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2004-04-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry